SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride and potassium chloride are electrolytes that maintain osmotic balance, fluid distribution, and proper cellular function. Sodium is the primary extracellular cation involved in fluid balance, nerve impulse transmission, and muscle contraction. Potassium is the major intracellular cation essential for cardiac, skeletal, and smooth muscle activity, and acid-base balance.
| Metabolism | Sodium and potassium are not metabolized; they are excreted unchanged primarily by the kidneys. |
| Excretion | Sodium and potassium ions are primarily excreted renally. Sodium elimination follows glomerular filtration with 99% tubular reabsorption, while potassium is filtered, then 90% is reabsorbed in proximal tubule and loop of Henle, with distal secretion regulated by aldosterone. Fecal excretion is minimal (<5%) under normal conditions. |
| Half-life | Sodium and potassium have no true terminal half-life as they are homeostatically regulated. In steady-state, sodium turnover half-life is approximately 2-3 weeks, while potassium has a faster turnover of about 40 hours in skeletal muscle. Clinically, redistribution after IV infusion occurs within hours, with renal excretion adapting rapidly. |
| Protein binding | Sodium and potassium ions are not significantly protein-bound; binding <1%. |
| Volume of Distribution | Sodium Vd is approximately 0.20-0.25 L/kg, equating to extracellular fluid volume. Potassium Vd is larger, approximately 0.5-0.6 L/kg, mainly distributing into intracellular fluid (98% of body potassium). |
| Bioavailability | Oral sodium chloride: nearly 100% absorbed. Oral potassium chloride: bioavailability 70-90% (due to some fecal loss and absorption variability). IV administration: 100% bioavailable. |
| Onset of Action | IV infusion: immediate electrolyte distribution and hemodynamic effects (within seconds to minutes). Rapid correction of hyponatremia or hypokalemia begins within minutes of infusion initiation. |
| Duration of Action | Duration depends on renal function and ongoing losses. For IV rehydration, effects last 2-6 hours; for potassium replacement, duration is until cellular uptake and renal excretion, typically 4-8 hours. Prolonged in renal impairment. |
Intravenous infusion; typical adult dose is 1-2 mL/kg/hr adjusted based on serum electrolyte levels and fluid status. For maintenance, 30 mL/kg/day of 0.9% sodium chloride with 0.075% potassium chloride (KCl 10 mEq/L) at a rate of 100-125 mL/hr. Not to exceed 20 mEq KCl per hour.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of hyperkalemia. For eGFR 30-60 mL/min/1.73m², reduce dose by 25-50% and monitor serum potassium closely. In oliguric patients, avoid unless documented hypokalemia and careful monitoring. |
| Liver impairment | No specific dose adjustment recommended per Child-Pugh class. Caution in severe hepatic impairment (Child-Pugh C) due to potential electrolyte disturbances; monitor serum potassium and chloride levels frequently. |
| Pediatric use | Weight-based: Intravenous infusion at 0.5-1 mL/kg/hr for maintenance, with potassium chloride at 0.5-1 mEq/kg/day. Do not exceed 0.5 mEq/kg/hr or 20 mEq/100 mL infusion fluid. Adjust based on serum electrolytes and hydration status. For neonates, use with caution and monitor renal function. |
| Geriatric use | Start at lower end of dosing range (1 mL/kg/hr) with careful monitoring of renal function and serum electrolytes due to age-related decline in renal function and increased risk of hyperkalemia. Avoid use in patients with eGFR <30 mL/min/1.73m². |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Sodium and potassium are normal constituents of breast milk; exogenous administration does not alter milk composition significantly. M/P ratio: not applicable. Compatible with breastfeeding. |
| Teratogenic Risk | Sodium chloride 0.9% and potassium chloride 0.075% are physiologic electrolytes; no teratogenic effects reported. No known fetal risk at any trimester when used as indicated. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Hypernatremia","Severe renal impairment (oliguria, anuria)","Uncontrolled Addison's disease","Edematous states with sodium retention (e.g., congestive heart failure, cirrhosis)"]
| Precautions | ["Use with caution in patients with heart failure, renal impairment, adrenal insufficiency, or cirrhosis with ascites.","Monitor serum electrolytes, fluid balance, and renal function during therapy.","Avoid rapid infusion or excessive volume to prevent fluid overload, hyperkalemia, or hypernatremia.","Potassium-containing solutions should be administered with caution in patients on potassium-sparing diuretics or ACE inhibitors."] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium) and fluid balance, especially in cases of prolonged infusion or patient with renal/cardiac impairment. Assess for signs of hypernatremia or hyperkalemia. |
| Fertility Effects | No known effects on fertility. Not studied but expected to have no impact due to physiologic nature. |